PLK4: a Promising Target for Cancer Therapy

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2019 Sep 8

PMID 31492983

Citations 30

Authors

Yi Zhao

Xin Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic defects, chromosomal instability and, consequently, tumorigenesis. Therefore, PLK4 has emerged as a therapeutic target for the treatment of multiple cancers. In this review, we summarize the critical role of centrosome amplification and PLK4 in cancer. We also highlight recent advances in the development of PLK4 inhibitors and discuss potential combination therapies for cancer.

Methods: The relevant literature from PubMed is reviewed in this article. The ClinicalTrials.gov database was searched for clinical trials related to the specific topic.

Results: PLK4 is aberrantly expressed in multiple cancers and has prognostic value. Targeting PLK4 with inhibitors suppresses tumor growth in vitro and in vivo.

Conclusions: PLK4 plays an important role in centrosome amplification and tumor progression. PLK4 inhibitors used alone or in combination with other drugs have shown significant anticancer efficacy, suggesting a potential therapeutic strategy for cancer. The results of relevant clinical trials await evaluation.

Citing Articles

Reversal of the tamoxifen‑resistant breast cancer malignant phenotype by proliferation inhibition with bromosulfonamidine amino‑podophyllotoxin.

Wang J, Lv F, Zhu Y, Lu X, Zhang B Oncol Lett. 2024; 28(2):373.

PMID: 38910903 PMC: 11190816. DOI: 10.3892/ol.2024.14506.

Centrosomes and associated proteins in pathogenesis and treatment of breast cancer.

Athwal H, Kochiyanil A, Bhat V, Allan A, Parsyan A Front Oncol. 2024; 14:1370565.

PMID: 38606093 PMC: 11007099. DOI: 10.3389/fonc.2024.1370565.

Explore Key Genes and Mechanisms Involved in Colon Cancer Progression Based on Bioinformatics Analysis.

Lan Y, Yang X, Wei Y, Tian Z, Zhang L, Zhou J Appl Biochem Biotechnol. 2024; 196(9):6253-6268.

PMID: 38294732 DOI: 10.1007/s12010-023-04812-3.

Design, synthesis, and biological evaluation of novel pyrimidin-2-amine derivatives as potent PLK4 inhibitors.

Xue Y, Mu S, Sun P, Sun Y, Liu N, Sun Y RSC Med Chem. 2023; 14(9):1787-1802.

PMID: 37731702 PMC: 10507801. DOI: 10.1039/d3md00267e.

PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.

Zhu W, Xie B Cancer Biol Ther. 2023; 24(1):2223383.

PMID: 37351847 PMC: 10292002. DOI: 10.1080/15384047.2023.2223383.

References

Anderhub S, Kramer A, Maier B . Centrosome amplification in tumorigenesis. Cancer Lett. 2012; 322(1):8-17. DOI: 10.1016/j.canlet.2012.02.006. View

Archambault V, Lepine G, Kachaner D . Understanding the Polo Kinase machine. Oncogene. 2015; 34(37):4799-807. DOI: 10.1038/onc.2014.451. View

Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z . MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis. 2018; 9(10):1045. PMC: 6185973. DOI: 10.1038/s41419-018-1020-0. View

Boveri T . Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci. 2008; 121 Suppl 1:1-84. DOI: 10.1242/jcs.025742. View

Coelho P, Bury L, Shahbazi M, Liakath-Ali K, Tate P, Wormald S . Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse. Open Biol. 2015; 5(12):150209. PMC: 4703062. DOI: 10.1098/rsob.150209. View

Cunha-Ferreira I, Rodrigues-Martins A, Bento I, Riparbelli M, Zhang W, Laue E . The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4. Curr Biol. 2008; 19(1):43-9. DOI: 10.1016/j.cub.2008.11.037. View

Denu R, Zasadil L, Kanugh C, Laffin J, Weaver B, Burkard M . Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer. 2016; 16:47. PMC: 4734858. DOI: 10.1186/s12885-016-2083-x. View

Denu R, Shabbir M, Nihal M, Singh C, Longley B, Burkard M . Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Mol Cancer Res. 2018; 16(3):517-527. PMC: 5835182. DOI: 10.1158/1541-7786.MCR-17-0197. View

Fischer M, Quaas M, Wintsche A, Muller G, Engeland K . Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein. Nucleic Acids Res. 2013; 42(1):163-80. PMC: 3874167. DOI: 10.1093/nar/gkt849. View

10.

Fischer M, Quaas M, Steiner L, Engeland K . The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res. 2015; 44(1):164-74. PMC: 4705690. DOI: 10.1093/nar/gkv927. View

11.

Fournier M, Orpinell M, Grauffel C, Scheer E, Garnier J, Ye T . KAT2A/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in preventing centrosome amplification. Nat Commun. 2016; 7:13227. PMC: 5095585. DOI: 10.1038/ncomms13227. View

12.

Gemble S, Basto R . Fast and furious . . . or not, Plk4 dictates the pace. J Cell Biol. 2018; 217(4):1169-1171. PMC: 5881513. DOI: 10.1083/jcb.201802084. View

13.

Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C . Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014; 510(7503):167-71. PMC: 4061398. DOI: 10.1038/nature13277. View

14.

Gonczy P . Centrosomes and cancer: revisiting a long-standing relationship. Nat Rev Cancer. 2015; 15(11):639-52. DOI: 10.1038/nrc3995. View

15.

Habedanck R, Stierhof Y, Wilkinson C, Nigg E . The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol. 2005; 7(11):1140-6. DOI: 10.1038/ncb1320. View

16.

Helmke C, Becker S, Strebhardt K . The role of Plk3 in oncogenesis. Oncogene. 2015; 35(2):135-47. DOI: 10.1038/onc.2015.105. View

17.

Holland A, Cleveland D . Polo-like kinase 4 inhibition: a strategy for cancer therapy?. Cancer Cell. 2014; 26(2):151-3. PMC: 4148003. DOI: 10.1016/j.ccr.2014.07.017. View

18.

Holland A, Lan W, Niessen S, Hoover H, Cleveland D . Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. J Cell Biol. 2010; 188(2):191-8. PMC: 2813471. DOI: 10.1083/jcb.200911102. View

19.

Holland A, Fachinetti D, Da Cruz S, Zhu Q, Vitre B, Lince-Faria M . Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis. Mol Biol Cell. 2012; 23(10):1838-45. PMC: 3350549. DOI: 10.1091/mbc.E11-12-1043. View

20.

Hudnall S, Meng H, Lozovatsky L, Li P, Strout M, Kleinstein S . Recurrent genetic defects in classical Hodgkin lymphoma cell lines. Leuk Lymphoma. 2016; 57(12):2890-2900. DOI: 10.1080/10428194.2016.1177179. View